Shield Therapeutics (STX) has released H117 interims that show in-market Feraccru sales of £0.2m (flat YoY) with an adj. net loss of £8.4m (+65% from H1-16). Sales & marketing costs have been increased in response to management identifying commercialisation headwinds. Net cash of £21.5m takes STX through to AEGIS-CKD readout in Q118, after which management will have clearer visibility on marketing cash outflows going forward. We revise FY17/18 sales forecasts down by 37%
22 Sep 2017
Interims – EU headwinds quickly dealt with
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interims – EU headwinds quickly dealt with
Shield Therapeutics Plc (STX:LON) | 1.4 0 0.0% | Mkt Cap: 11.1m
- Published:
22 Sep 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
8
Shield Therapeutics (STX) has released H117 interims that show in-market Feraccru sales of £0.2m (flat YoY) with an adj. net loss of £8.4m (+65% from H1-16). Sales & marketing costs have been increased in response to management identifying commercialisation headwinds. Net cash of £21.5m takes STX through to AEGIS-CKD readout in Q118, after which management will have clearer visibility on marketing cash outflows going forward. We revise FY17/18 sales forecasts down by 37%